Faeth Therapeutics Raises $47M in Series A Funding
- Faeth Therapeutics, a San Francisco, CA-based cancer metabolism company, raised $47M in Series A funding
- The round, which brings total funding to date to $67m, was led by S2G Ventures, with participation from Khosla Ventures, Future Ventures, Digitalis, KdT Ventures, AgFunder, and Cantos
- The company intends to use the funds to advance its clinical trials that combine nutrient control, therapeutics and digital tools to inhibit cancer metabolism
- The proceeds of the round will be used to support early phase clinical trials focusing on the safety of its approaches in cancer patients
- Faeth Therapeutics leverages an approach that includes precisely targeted nutrient control, therapeutics, and digital tools to support both the patient and clinician
